Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer Ag S/Adr (BAYRY)

Bayer Ag S/Adr (BAYRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 53,561,808
  • Shares Outstanding, K 3,929,700
  • Annual Sales, $ 50,432 M
  • Annual Income, $ -2,762 M
  • EBIT $ 3,627 M
  • EBITDA $ 13,131 M
  • 60-Month Beta 0.68
  • Price/Sales 1.06
  • Price/Cash Flow 3.64
  • Price/Book 1.56
  • Price/Earnings ttm 9.39
  • Earnings Per Share ttm 1.45
  • Most Recent Earnings $0.17 on 11/12/25
  • Next Earnings Date 03/04/26 [--]
  • Annual Dividend & Yield (Fwd) 0.02 (0.17%)
  • Most Recent Dividend 0.023 on 04/29/25
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.17
  • Number of Estimates 2
  • High Estimate 0.19
  • Low Estimate 0.16
  • Prior Year 0.28
  • Growth Rate Est. (year over year) -39.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.2500 +21.16%
on 01/13/26
13.9800 -2.50%
on 01/27/26
+2.3400 (+20.73%)
since 01/09/26
3-Month
7.6500 +78.17%
on 11/20/25
13.9800 -2.50%
on 01/27/26
+5.7150 (+72.20%)
since 11/11/25
52-Week
5.3000 +157.17%
on 04/07/25
13.9800 -2.50%
on 01/27/26
+8.1600 (+149.18%)
since 02/11/25

Most Recent Stories

More News
Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month

This February, the brand continues its See Your Risks initiative by challenging denial and bringing unseen heart health risk factors into view.

BAYRY : 13.7850 (+1.14%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significantly less likely to suffer a secondary stroke compared...

BAYRY : 13.7850 (+1.14%)
BAYZF : 54.8050 (-0.08%)
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign

‘Highlights REAL’ aims to spark vital conversations about advanced prostate cancer and educate about the importance of treatment management

BAYRY : 13.7850 (+1.14%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada

Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada’s leadership in canola innovation by establishing a cutting-edge canola innovation centre. Located...

BAYRY : 13.7850 (+1.14%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention

Findings from OCEANIC-STROKE, including the main results and a prespecified subgroup analysis, will be presented for the first time during two late-breaking sessions at the International Stroke Conference...

BAYRY : 13.7850 (+1.14%)
BAYZF : 54.8050 (-0.08%)
Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases

Not intended for UK Media Collaboration spans across various indications with an initial focus on cardiovascular and kidney diseases, addressing areas of significant...

BAYRY : 13.7850 (+1.14%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Bayer Accelerates Pharma Growth on High-Value Portfolio

Bayer is successfully executing on an ambitious growth strategy Five pivotal approvals worldwide in 2025 underscore a landmark year of strategic execution Bayer will...

BAYRY : 13.7850 (+1.14%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause

In the ‘Life Doesn’t Stop for a Hot Flash’ campaign, Gabrielle Union-Wade and Bayer partner together to help raise awareness about an available treatment option for moderate to severe hot flashes...

BAYRY : 13.7850 (+1.14%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus

Not intended for UK Media Bayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance diagnosis...

BAYRY : 13.7850 (+1.14%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

Not intended for UK Media Collaboration focuses on developing potential best in class siRNA-based treatment for a form of dilated cardiomyopathy Bayer...

BAYRY : 13.7850 (+1.14%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses....

See More

Key Turning Points

3rd Resistance Point 13.9367
2nd Resistance Point 13.8233
1st Resistance Point 13.7267
Last Price 13.7850
1st Support Level 13.5167
2nd Support Level 13.4033
3rd Support Level 13.3067

See More

52-Week High 13.9800
Last Price 13.7850
Fibonacci 61.8% 10.6642
Fibonacci 50% 9.6400
Fibonacci 38.2% 8.6158
52-Week Low 5.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar